23andMe has created a new therapeutics unit and appointed Dr Richard Scheller chief science officer and head of therapeutics in order to lead it. Dr Scheller retired in December 2014 after 14 years at Genentech where he was the executive vice-president of research and early development.
23andMe appoints ex-Genentech exec to lead new therapeutics unit
23andMe has created a new therapeutics unit and appointed Dr Richard Scheller chief science officer and head of therapeutics in order to lead it. Dr Scheller retired in December 2014 after 14 years at Genentech where he was the executive vice-president of research and early development.
More from Neurological
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.